337 related articles for article (PubMed ID: 29245294)
1. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH
Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294
[TBL] [Abstract][Full Text] [Related]
2. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
Jang BG; Lee HE; Kim WH
Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
[TBL] [Abstract][Full Text] [Related]
3. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
4. Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
Brown JB; Pai RK; Burgess MA; Chennat J; Zureikat AH
J Natl Compr Canc Netw; 2018 Dec; 16(12):1424-1428. PubMed ID: 30545989
[TBL] [Abstract][Full Text] [Related]
5. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
[TBL] [Abstract][Full Text] [Related]
6. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
7. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
8. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
9. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM
Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284
[TBL] [Abstract][Full Text] [Related]
10. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
[TBL] [Abstract][Full Text] [Related]
11. An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy.
Vassos N; Agaimy A; Schlabrakowski A; Hohenberger W; Schneider-Stock R; Croner RS
Virchows Arch; 2011 Mar; 458(3):363-9. PubMed ID: 21191613
[TBL] [Abstract][Full Text] [Related]
12. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.
Kang GH; Srivastava A; Kim YE; Park HJ; Park CK; Sohn TS; Kim S; Kang DY; Kim KM
Mod Pathol; 2011 Jun; 24(6):866-75. PubMed ID: 21358619
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
14. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
Miettinen M; Wang ZF; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013
[TBL] [Abstract][Full Text] [Related]
15. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach.
Wada T; Tanabe S; Ishido K; Higuchi K; Sasaki T; Katada C; Azuma M; Naruke A; Kim M; Koizumi W; Mikami T
World J Gastroenterol; 2013 Dec; 19(47):9133-6. PubMed ID: 24379641
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
[TBL] [Abstract][Full Text] [Related]
17. A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma.
Riddle ND; Gonzalez RJ; Bridge JA; Antonia S; Bui MM
Cancer Control; 2011 Jul; 18(3):152-9. PubMed ID: 21666577
[TBL] [Abstract][Full Text] [Related]
18. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Bosbach B; Deshpande S; Rossi F; Shieh JH; Sommer G; de Stanchina E; Veach DR; Scandura JM; Manova-Todorova K; Moore MA; Antonescu CR; Besmer P
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):E2276-83. PubMed ID: 22652566
[TBL] [Abstract][Full Text] [Related]
19. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
20. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]